Krystal Biotech, Inc. (FRA:4KB)
222.80
-17.40 (-7.24%)
At close: Feb 20, 2026
Krystal Biotech Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 496.3 | 344.87 | 358.33 | 161.9 | 341.25 |
Short-Term Investments | 331.49 | 252.65 | 173.85 | 217.27 | 96.85 |
Cash & Short-Term Investments | 827.79 | 597.52 | 532.18 | 379.17 | 438.1 |
Cash Growth | 38.54% | 12.28% | 40.35% | -13.45% | 61.50% |
Receivables | 127.43 | 104.75 | 42.04 | - | - |
Inventory | 40.48 | 26.51 | 6.99 | - | - |
Prepaid Expenses | 28.91 | 13.27 | 6.71 | 4.61 | 4.17 |
Total Current Assets | 1,025 | 742.05 | 587.91 | 383.78 | 442.27 |
Property, Plant & Equipment | 158.02 | 161.45 | 168.23 | 169.73 | 119.58 |
Long-Term Investments | 128.07 | 152.11 | 61.95 | 4.62 | 64.37 |
Long-Term Deferred Tax Assets | 22.82 | - | - | - | - |
Other Long-Term Assets | 0.29 | 0.23 | 0.26 | 0.32 | 0.07 |
Total Assets | 1,334 | 1,056 | 818.36 | 558.45 | 626.3 |
Accounts Payable | 3.24 | 4.99 | 4.13 | 3.98 | 8.4 |
Accrued Expenses | 81.25 | 52.78 | 18.15 | 11.54 | 6.52 |
Current Portion of Leases | 1.77 | 1.22 | 1.47 | 1.56 | 1.04 |
Current Income Taxes Payable | 10.92 | 4.29 | 1.96 | 0.04 | 0.08 |
Other Current Liabilities | 5.77 | 38.73 | 7.38 | 11.72 | 9.69 |
Total Current Liabilities | 102.94 | 102 | 33.09 | 28.85 | 25.74 |
Long-Term Leases | 7.57 | 6.04 | 6.62 | 7.37 | 6.98 |
Other Long-Term Liabilities | 3.72 | 1.42 | - | - | - |
Total Liabilities | 114.23 | 109.46 | 39.71 | 36.22 | 32.72 |
Additional Paid-In Capital | 1,194 | 1,127 | 1,048 | 803.72 | 734.52 |
Retained Earnings | 24.16 | -180.67 | -269.83 | -280.76 | -140.78 |
Comprehensive Income & Other | 1.14 | -0.19 | 0.64 | -0.73 | -0.16 |
Total Common Equity | 1,220 | 946.38 | 778.64 | 522.23 | 593.58 |
Shareholders' Equity | 1,220 | 946.38 | 778.64 | 522.23 | 593.58 |
Total Liabilities & Equity | 1,334 | 1,056 | 818.36 | 558.45 | 626.3 |
Total Debt | 9.34 | 7.26 | 8.09 | 8.93 | 8.02 |
Net Cash (Debt) | 946.52 | 742.37 | 586.04 | 374.86 | 494.44 |
Net Cash Growth | 27.50% | 26.68% | 56.34% | -24.19% | 84.97% |
Net Cash Per Share | 31.60 | 24.96 | 21.12 | 14.70 | 22.28 |
Filing Date Shares Outstanding | 29.23 | 28.81 | 28.29 | 25.76 | 25.21 |
Total Common Shares Outstanding | 29.19 | 28.79 | 28.24 | 25.76 | 25.21 |
Working Capital | 921.66 | 640.05 | 554.82 | 354.93 | 416.53 |
Book Value Per Share | 41.78 | 32.87 | 27.58 | 20.27 | 23.55 |
Tangible Book Value | 1,220 | 946.38 | 778.64 | 522.23 | 593.58 |
Tangible Book Value Per Share | 41.78 | 32.87 | 27.58 | 20.27 | 23.55 |
Buildings | 109.24 | 111.44 | 111.18 | - | - |
Machinery | 37.48 | 34.19 | 30.49 | 12.93 | 6.51 |
Construction In Progress | 8.11 | 5.78 | 7.29 | 131.33 | 104.34 |
Leasehold Improvements | 27.23 | 25.67 | 25.07 | 24.22 | 5.72 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.